Enzastaurin + Placebo

Phase 3Active

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Vascular Ehlers-Danlos Syndrome

Conditions

Vascular Ehlers-Danlos Syndrome

Trial Timeline

Jan 1, 2025 → Mar 1, 2027

NCT ID

NCT05463679

About Enzastaurin + Placebo

Enzastaurin + Placebo is a phase 3 stage product being developed by Aytu BioScience for Vascular Ehlers-Danlos Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT05463679. Target conditions include Vascular Ehlers-Danlos Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05463679	Phase 3	Active	Jan 1, 2025	Mar 1, 2027	Vascular Ehlers-Danlos Syndrome

Competing Products

20 competing products in Vascular Ehlers-Danlos Syndrome

See all competitors

Product	Company	Stage	Hype Score
CLS-AX + Anti-VEGF	Clearside Biomedical	Phase 1/2	33
CLS-AX + Aflibercept	Clearside Biomedical	Phase 2	44
Eylea + ALT-L9	Alteogen	Phase 1	33
Dulaglutide + Placebo	Eli Lilly	Phase 3	77
raloxifene + placebo	Eli Lilly	Phase 3	77
Evacetrapib	Eli Lilly	Phase 1	33
Orforglipron + Placebo	Eli Lilly	Phase 3	77
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)	Unity Biotechnology	Phase 2	44
Prasugrel (CS-747) + Clopidogrel	Eli Lilly	Phase 2	52
Rosuvamibe + Monorova	Yuhan	Approved	85
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin	Yuhan	Approved	85
Rosuvamibe + Monorova	Yuhan	Approved	85
olmesartan	Daiichi Sankyo	Pre-clinical	23
DS-7080a + Ranibizumab	Daiichi Sankyo	Phase 1	33
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)	Daiichi Sankyo	Approved	85
Avacincaptad Pegol	Astellas Pharma	Phase 1	33
Avacincaptad Pegol + Avastin + Lucentis + Eylea	Astellas Pharma	Phase 2	52
Lexiscan	Astellas Pharma	Phase 2	52
YM872 (zonampanel)	Astellas Pharma	Phase 2	52
Avacincaptad Pegol + Lucentis	Astellas Pharma	Phase 2	52

Other Products from Aytu BioScience

ADZENYS XR-ODT + Placebo Oral TabletApproved